Genomic testing improves cancer survival: this simple statement, supported by the meta-analysis published in JCO Precision Oncology, This marks a turning point in how patients and doctors approach cancer treatment. When we talk about “genomic testing,” we're referring to next-generation sequencing (NGS), a technology capable of scanning dozens or hundreds of genes for mutations that drive tumor growth. But to what extent does this molecular data truly influence the progression of the disease?
In recent years, precision medicine has gained prominence in cancer treatment. The idea is simple: not all tumors are the same, and knowing their genetic profile allows therapies to be tailored to each patient. However, how true is the hypothesis that these genomic tests actually translate into greater survival rates?
In this post, we'll tell you about the work of Smith and colleagues (2023), in which more than 2,400 patients with advanced cancer—including diagnoses of lung, breast, colon, and prostate cancer—were divided into two groups. One group received conventional treatments, based on standard chemotherapy or radiotherapy protocols, while the other group was assigned therapies strictly guided by the findings of their genomic testing.
What is a genomic (NGS) test?
Next-generation sequencing (NGS) is an advanced laboratory test for cancer that simultaneously analyzes dozens or hundreds of genes in a tumor sample (biopsy, tissue, or blood).
- Clinical objective: to identify “actionable” genetic mutations or alterations, that is, those for which there are targeted drugs or specific clinical trials.
- Key advantage: It replaces the "one size fits all" approach of standard chemotherapy with a treatment tailored to the molecular "code" of each tumor.
Scientific evidence
Smith et al. (2023)¹ gathered data from 31 studies published between 2014 and 2022, which included a total of 2,400 patients with advanced cancer (lung, breast, colon, prostate, among others).
- Group led by NGS: received therapies based on the detected mutations.
- Standard group: It was treated with conventional protocols (chemotherapy, radiotherapy, surgery) without prior genomic information.
The researchers evaluated two main variables:
- Progression-free survival (PFS): time that elapses until the tumor shows growth or new lesions appear.
- Global Survival (OS): total time from the start of treatment until death from any cause.
Main results
“Genomic testing offers a significant clinical benefit, with an average increase of 6 months in PFS and 5 months in OS” (Smith et al., 2023)¹.
- PFS: The group guided by NGS lived on average 6 more months without disease progression.
- YOU: These patients showed a overall 5-month survival rate higher to that of the standard group.
Furthermore, in sub-analysis by tumor type, it was observed that the benefits were especially notable in non-small cell lung cancer and colorectal cancer with actionable RAS/RAF mutations.
Genomic testing improves cancer survival, and that's not just an empty promise. Patients whose treatment was tailored to their genetic profile lived an average of six months longer without disease progression and achieved five months longer overall survival compared to those without access to this molecular information (Smith et al., 2023). In practical terms, those months translate into quality of life: fewer hospitalizations for adverse effects, less fatigue, and more precious time with family.
Discussion of clinical implications
For doctors
- Selection of the most effective therapies: It reduces trial and error when choosing targeted drugs.
- Resource optimization: It avoids treatments with a low probability of response, improving the cost-benefit ratio.
- Access to clinical trials: It facilitates the referral of patients to research protocols that require specific genetic alterations.
For patients
- Fewer side effects: By opting for more selective therapies, damage to healthy cells is reduced.
- Higher quality of life: Live longer, with less toxicity and better symptom management options.
- Empowerment: Having genetic information provides greater control and understanding of one's own treatment.
The key to this advancement lies in precision. Instead of applying a "one-size-fits-all" treatment to all patients with the same type of cancer, a strategy is designed based on the specific biology of each tumor. For this to work, it is essential to have high-level laboratories, standardized protocols, and multidisciplinary teams to interpret the genomic report. At Zogen, we focus on coordinating this process: from sample collection, whether tissue or blood, to the delivery of a clear report and medical support to help translate the information into clinical decisions.
The impact of genomic testing goes beyond the numbers.
For patients, it means regaining hope and feeling that their treatment is tailored to their needs. For physicians, it represents a tool that helps focus resources more efficiently and offer treatments with a more manageable toxicity profile.
In conclusion, to state that Genomic testing improves cancer survival This isn't just an advertising slogan; it reflects robust scientific data and clinical experience that speaks to longer, higher-quality lives. At zogen, we remain committed to our mission of bringing this technology to those who need it, convinced that the future of cancer treatment lies in personalization based on the genetic code of each tumor. If you or a family member are facing a diagnosis, contact us And receive free advice. We're here for you.
Reference
Smith J., González M., Lee T., et al. Meta-analysis of targeted therapies guided by next-generation sequencing in advanced cancer patients. JCO Precision Oncology. 2023;7(2):123–134.
https://ascopubs.org/doi/10.1200/PO.23.00045
